Nautilus Biotechnology, Inc. (NAUT): Price and Financial Metrics
GET POWR RATINGS... FREE!
NAUT Stock Price Chart Interactive Chart >
NAUT Price/Volume Stats
| Current price | $1.96 | 52-week high | $5.07 |
| Prev. close | $1.93 | 52-week low | $1.50 |
| Day low | $1.93 | Volume | 77,377 |
| Day high | $2.01 | Avg. volume | 146,259 |
| 50-day MA | $1.79 | Dividend yield | N/A |
| 200-day MA | $2.56 | Market Cap | 244.46M |
Nautilus Biotechnology, Inc. (NAUT) Company Bio
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating platform technology for quantifying and unlocking the complexity of the proteome. It operates Nautilus Proteomic Analysis Platform, an integrated single-molecule protein analysis platform that leverages a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to potentially identify and quantify the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington.
Latest NAUT News From Around the Web
Below are the latest news stories about NAUTILUS BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate NAUT as an investment opportunity.
Nautilus Biotechnology Launches “First Access Challenge”Open competition allows researchers to be among the first to access potentially groundbreaking proteomic data through the testing of twelve samples on Nautilus’ single-molecule protein analysis platform Open competition allows researchers to be among the first to access potentially groundbreaking proteomic data through the testing of twelve samples on Nautilus’ single-molecule protein analysis platform |
Nautilus Biotechnology Reports Third Quarter 2022 Financial ResultsSEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2022. |
Nautilus Biotechnology, Inc. (NAUT) Q3 2022 Earnings Call TranscriptNautilus Biotechnology, Inc. (NASDAQ:NASDAQ:NAUT) Q3 2022 Earnings Conference Call November 01, 2022, 08:30 AM ET Company Participants Sujal Patel - Co-Founder and CEO Parag Mallick -… |
Nautilus Biotechnology GAAP EPS of -$0.11 beats by $0.03Nautilus Biotechnology press release (NAUT): Q3 GAAP EPS of -$0.11 beats by $0.03.Cash, cash equivalents, and investments were $323.6M as of September 30, 2022. |
Nautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter 2022 before market open on Tuesday, November 1, 2022. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, |
NAUT Price Returns
| 1-mo | 8.89% |
| 3-mo | -10.50% |
| 6-mo | -30.50% |
| 1-year | -50.00% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 8.89% |
| 2022 | -65.25% |
| 2021 | -52.26% |
| 2020 | N/A |
| 2019 | 0.00% |
| 2018 | N/A |
Loading social stream, please wait...